Pacific Century Premium Developments Limited (PCPDF)

CTI BioPharma Cash Flow Statement

Financials in millions HKD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-	-230	-466	-598	-825	-749
Depreciation & Amortization	-	174	173	195	210	235
Loss (Gain) From Sale of Assets	-	-	-	-109	6	2
Asset Writedown & Restructuring Costs	-	-131	-	-	-	229
Other Operating Activities	-	289	341	343	414	249
Change in Accounts Receivable	-	-9	-37	-25	-7	-4
Change in Inventory	-	-149	-193	-50	-38	1,107
Change in Accounts Payable	-	-6	8	-1	-178	-408
Change in Unearned Revenue	-	32	115	-15	11	-335
Change in Other Net Operating Assets	-	-45	304	361	14	317
Operating Cash Flow	-	-75	245	101	-392	646
Operating Cash Flow Growth	-	-	142.57%	-	-	687.80%
Capital Expenditures	-	-70	-74	-56	-262	-199
Sale of Property, Plant & Equipment	-	-	-	-	2	-
Sale (Purchase) of Real Estate	-	-3	-	-	-1	-12
Investment in Securities	-	-	90	1,852	-1,942	-
Investing Cash Flow	-	-73	16	1,796	-2,203	-211
Long-Term Debt Issued	-	513	534	233	6,991	-
Long-Term Debt Repaid	-	-75	-84	-2,515	-3,981	-765
Net Debt Issued (Repaid)	-	438	450	-2,282	3,010	-765
Issuance of Common Stock	-	-	-	-	364	-
Other Financing Activities	-	-517	-441	-476	-431	142
Financing Cash Flow	-	-79	9	-2,758	2,943	-623
Foreign Exchange Rate Adjustments	-	21	-1	-59	-34	12
Net Cash Flow	-	-206	269	-920	314	-176
Free Cash Flow	-	-145	171	45	-654	447
Free Cash Flow Growth	-	-	280.00%	-	-	-
Free Cash Flow Margin	-	-16.09%	20.80%	8.02%	-140.04%	24.25%
Free Cash Flow Per Share	-	-0.07	0.08	0.02	-0.34	0.28
Cash Interest Paid	-	489	451	441	424	323
Cash Income Tax Paid	-	48	58	52	58	48
Levered Free Cash Flow	-	-350.5	-2,863	-65.75	-733.13	887.63
Unlevered Free Cash Flow	-	-132.38	-2,661	143	-530	1,057
Change in Net Working Capital	362	217	2,704	-209	248	-1,173

Source: S&P Global Market Intelligence. Standard template. Financial Sources.